

COVID-19 vaccine effectiveness in children under 5 in the USA: a test-negative case-control study

Rachel A. Silverman, PhD, ScM^a, Monica L. Ahrens, PhD^b, Meagan Helmick, PhD, MPH^c,
Carla V. Finkielstein, PhD^{d,e}, Alasdair Cohen, PhD, MPH, MSc^f, Erica Short, MPH^c, Paige
Bordwine, MPH^c

Affiliations: ^aCenter for Biostatistics and Health Data Science, Virginia Tech, Roanoke, Virginia; ^bMedical Informatics, University of Kansas Medical Center, Kansas City, Kansas; ^cVirginia Department of Health, Richmond, Virginia; ^dFralin Biomedical Research Institute at Virginia Tech Carilion, Roanoke, Virginia; ^eDepartment of Biological Sciences, College of Science, Virginia Tech, Blacksburg, Virginia; and ^fDepartment of Population Health Sciences, Virginia Tech, Blacksburg, Virginia

Address correspondence to: Rachel Silverman, Center for Biostatistics and Health Data Science, Four Riverside Circle, Roanoke, VA 24016. [rsilverman@vt.edu].

Short Title: COVID-19 vaccine effectiveness in children under 5

Conflict of Interest Disclosures: The authors have no conflicts of interest relevant to this article to disclose.

Funding/Support: This project was supported by an Interdisciplinary Team-Building Pilot Grant from the Virginia Tech Center for Emerging, Zoonotic, and Arthropod-borne Pathogens for 2022-23, a Go Virginia Economic Resilience and Recovery Grant (20-GOVA-ERR-02A and 20-GOVA-ERR-02D), the Department of General Services of the Commonwealth of Virginia (DGS-201020-UVT), and funds from Virginia Tech, the Fralin Biomedical Research Institute at Virginia Tech Carilion, and the Fralin Life Sciences Institute.

Role of Funder/Sponsor: The funders had no role in the design and conduct of this study.

Abbreviations:

AAP: American Academy of Pediatrics
ACIP: Advisory Committee on Immunization Practices
AIC: Akaike information criterion
CDC: Centers for Disease Control and Prevention
CI: Confidence interval
COVID-19: Coronavirus disease 2019
FDA: Food and Drug Administration
IRB: Institutional Review Boards
OR: Odds ratio
SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2
SWVA: Southwest Virginia
VDH: Virginia Department of Health
VE: Vaccine effectiveness
VEDSS: Virginia Electronic Disease Surveillance System

VIIS: Virginia Immunization Information System

What's Known on This Subject

SARS-CoV-2 (COVID-19) continues to mutate, circulate, and adversely impact health and quality of life. While research continues to show that COVID-19 vaccines remain safe and effective, uptake remains low, especially among young children who were not vaccine-eligible until after Omicron.

What This Study Adds

Children under-5 are underrepresented in published COVID-19 vaccine effectiveness research. This test negative case-control study estimates VE in this age-group following vaccine approval after the 2022 Omicron wave, using surveillance data from the Virginian Department of Health in Southwest Virginia.

Contributors Statement Page

Dr. Rachel Silverman conceptualized and designed the study, conducted all data analyses, and drafted and finalized the manuscript.

Dr. Monica Ahrens consulted on and validated the methods and critically reviewed and revised the manuscript.

Dr. Alasdair Cohen consulted on data analysis methods and critically reviewed and revised the manuscript.

Dr. Carla Finkielstein validated the data tables and critically reviewed and revised the manuscript.

Dr. Meagan Helmick was involved in data collection and validation, consulted on the methods and critically reviewed and revised the manuscript.

Erica Short and Paige Bordwine were involved in data collection and validation and critically reviewed and revised the manuscript.

All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

Abstract

Background and Objectives: SARS-CoV-2 (COVID-19) continues to mutate, circulate, and adversely impact health and quality of life. While COVID-19 vaccines remain safe and effective, uptake remains low, especially among children, the youngest of whom were not vaccine-eligible until after Omicron and are underrepresented in published research. This study estimated vaccine effectiveness (VE) among under-5-year-olds.

Methods: We used Virginia Department of Health surveillance data from June 2022 through October 2022 to conduct a test negative case-control study. We estimated VE derived from odds ratios (ORs) of reported infections using logistic regression among children aged 6-months to 5-years.

Results: Using the earliest positive (cases) or negative (controls) post-vaccine-eligible test results, the VE associated with two doses of a COVID-19 vaccine was 78% (95% CI=45%, 93%; $p=0.004$) in unadjusted analyses and 70% (95% CI=25%, 91%, $p=0.023$) when adjusting for age, sex, prior testing behavior, and prior reported infections. The adjusted VE was 74% (95% CI=28%, 94%; $p=0.025$) among those with no prior positives reported and 45% (95% CI=302%, 97%; $p=0.569$) among those with a prior positive reported.

Conclusions: These results show that even though the vaccine was not closely matched to the dominant variants circulating during the time period analyzed, it was effective at reducing the risk of reported infections. This study adds to the body of knowledge on pediatric COVID-19 VE in an underrepresented age-group and in a rural region, illustrates the utility of surveillance data for evaluation, and can inform vaccine decisions to improve vaccine uptake for young children.

Background

While coronavirus disease 2019 (COVID-19) continues to adversely impact health and quality of life,¹⁻⁴ COVID-19 vaccines remain safe and effective at reducing illness and disease severity across populations.⁵⁻¹⁴ However, SARS-CoV-2 continues to mutate, generating variants with variable transmissibility and disease severity,^{2, 15-18} and it has been shown repeatedly that VE declines as immunity wanes and immune-escaping variants emerge,^{10, 11, 13, 14} including among children.¹⁴ Though at lower risk for serious illness than adults, some children do become severely ill¹⁹⁻²² and are at risk for post-acute sequelae of SARS-CoV-2 (or long-COVID).²³⁻³¹ Children are significant contributors to household transmission³²⁻³⁵ and illness can exacerbate health and economic disparities,³⁶ demonstrating the importance of reducing infection and illness risk across all age groups.

In early 2021, COVID-19 vaccines became available in the US to the general 16-and-older population, with lagging approval for pediatric age-groups (Figure 1).³⁷⁻⁶⁴ It was not until after the initial Omicron wave during the 2021/2022 winter⁴¹, driving an explosion of viral diversity⁴⁰ and leaving an estimated 75% of children with serologic evidence of a prior SARS-CoV-2 infection by February 2022,⁴² that the vaccines for the youngest group (6 months to <5 years of age) were first approved on June 18th, 2022.

COVID-19 Vaccines for SARS-CoV-2 are recommended and approved for everyone over 6 months of age by the FDA, CDC, ACIP, and the AAP,^{47, 48, 51, 52, 60, 61, 65} including with vaccines released annually in the fall that are updated to target recently dominating variants.^{38, 39, 64, 66} However, vaccine uptake among pediatric populations remains extremely low, particularly in marginalized communities and rural areas.⁶⁷⁻⁷⁰ Vaccine hesitancy among parents has increased, especially for COVID-19.⁷¹ According to the CDC, approximately 14.9% of children 6-months

to 17-years old were up-to-date with COVID-19 vaccines by the end of the 2023-2024 season, declining to 13.2% for 2024-2025.⁷⁰ Coverage was disproportionately low among rural pediatric populations, at 8.4% and 7.5% by end of these seasons, respectively.⁷⁰ Among children 6 months to 4 years, coverage was much lower at 6.7% and 5.9%, respectively.⁷⁰

While there is substantial research on the VE for the 5 and up age-groups,^{6-8, 72-94} only a few published studies exist that focus on children under 5 years old,⁹⁵⁻¹⁰⁰ and fewer focus on VE against reported infections^{96, 97} vs. hospitalizations for higher risk individuals.^{98, 100} Evaluating VE in diverse contexts informs policy makers, healthcare providers, and families in making vaccination decisions. Here, we estimated VE against reported COVID-19 infection among vaccine-eligible children under 5 using VDH surveillance data from rural Southwest Virginia.

Methods

We conducted a test-negative case-control study to estimate VE of the COVID-19 mRNA primary series for children aged 6 months to under 5 years between June 18 and October 31, 2022 — the date after which negative tests were no longer reported to VDH. Data were restricted to Southwest Virginia (SWVA) to ensure consistency and focus on a rural population.

This study was approved by the Institutional Review Boards (IRBs) of Virginia Tech (IRB#: 20-852) and the Virginia Department of Health (IRB#: 70046). The study was determined to be public health surveillance as defined in the US Department of Health and Human Services, Title 45 Code of Federal Regulations, §46 Protection of Human Subjects (45 CFR §46.102[I]), and thus informed consent was not required.

Data sources and linkage

All data were routinely collected and provided by VDH. COVID-19 case and laboratory data are stored in the Virginia Electronic Disease Surveillance System (VEDSS); vaccination data are stored in the Virginia Immunization Information System (VIIS). VDH linked these datasets via 85% confidence fuzzy matching on first name, last name, and date of birth, restricting records to individuals aged 6 months to 18 years with at least one test before October 31, 2022, living in SWVA. A unique identifier was created prior to de-identification to allow validation while protecting confidentiality.

Selection Criteria

Selection of records retained for analysis is outlined in Figure 2. Selected records included children aged 6 months to under 5 years with samples collected after their vaccine eligibility date, defined as June 22, 2022 (the earliest vaccine received in this cohort), or the date they turned 6 months old, up to October 31, 2022. Five controls were excluded for residing outside SWVA, and 3 individuals (1 case, 2 controls) were excluded due to invalid merged vaccine information in which their names and dates of births matched, but their age did not (were 10-14 years old), with a vaccine type inconsistent with their age and an administered date prior to eligibility.

Case and control definitions

Cases were defined as those who had at least one positive test reported after they were eligible for vaccination. Controls were defined as those who had at least one negative test (and no positive tests) reported after vaccination eligibility. Cases and Controls were selected irrespective of the number and results of tests dated prior to vaccine eligibility.

Variable Definitions

Age was calculated from date of birth to sample collection date and defined as continuous (days) and categorical by year of age (<1, 1 to <2, 2 to <3, 3 to 4, 4 to <5 years). Sex was binary (male vs. female). Race and ethnicity were combined into one categorical variable: Hispanic (irrespective of race), and non-Hispanic White, Black, Asian, or other; the “other” category included American Indian or Alaska Native and Native Hawaiian or Pacific Islander due to small numbers. Individuals reporting multiple races were assigned to the group with the smallest count in the dataset¹⁰¹. Health district (Alleghany, Central Virginia, Cumberland Plateau, Lenowisco, Mount Rogers, New River, Pittsylvania, Roanoke City, and West Piedmont)¹⁰² was assigned based on residence at the time of the test; for missing counties, assignment was based on ZIP code, with cross-county ZIPs assigned to the most populous county.

Prior reported infections were positive results reported to VDH at least 30 days apart and before vaccine eligibility; when multiple positives occurred within 30 days, only the earliest was retained. Prior test-seeking behavior was categorized as: 1) first-ever test (no tests prior to eligibility), 2) sporadic (1–3 tests), or 3) frequent (≥ 4 tests), excluding tests within 30 days of a prior positive. In multivariable regression, behavior was defined by the number of prior negative tests.

Vaccine status — the primary predictor — was categorized by number of doses (1–3), vaccine type (Pfizer-BioNTech or Moderna), and time since last dose. Because many controls had multiple negative tests, using vaccine status at the earliest test would underestimate VE (less opportunity to vaccinate), while using the most-recent test would overestimate it (more opportunity). To bound the VE estimates:

- For cases, the vaccine status at their first positive test post-vaccine eligibility was used in all analyses.
- For controls, separate analyses were conducted in which the vaccine status at the 1) earliest and 2) most-recent negative test post-vaccine eligibility was used.

To allow time for immunity induction, doses administered within 7 days of the test were grouped with the previous dose category (e.g., first dose within 7 days = unvaccinated; second dose within 7 days = 1 dose; third dose within 7 days = 2 doses).

Statistical Analyses

Descriptive statistics (mean, min, max, median for continuous; number and percent for categorical) were calculated for the full cohort and by case/control status at the earliest eligible test. Vaccine type and dose counts are described for cases and controls under both selection scenarios (earliest and most-recent).

Unadjusted and adjusted odds ratios (OR) comparing vaccinated (by dose count) to unvaccinated were estimated via logistic regression ($\alpha = 0.05$), adjusting for age, sex, race/ethnicity, prior positive infections, time since prior positives, and prior test-seeking behavior. AIC determined the optimal age parameterization; Health District was included in sensitivity analyses. Vaccine types were combined due to small numbers. Time since last dose was included to assess waning immunity. VE was calculated as $[VE = (1 - OR) \times 100]$.

All data cleaning and analyses were conducted using RStudio.^{103, 104} Some R code was partially generated using ChatGPT¹⁰⁵ and all code was manually reviewed to confirm accuracy. R packages include tidyverse,¹⁰⁶ gtsummary,¹⁰⁷ and epikit.¹⁰⁸ The complete R scripts and a limited dataset are available in the supplemental material.

Results

Demographics

The study included 7,165 individuals (5,178 controls and 1,987 cases; Table 1). The overall mean age was 2.6 years; cases were slightly younger than controls (2.32 vs. 2.68 years) and had nearly twice the proportion of infants under 1 year (23% vs. 13%). Sex distribution was similar between groups (47% female overall, <1% missing). Race/ethnicity data were missing in 44% of controls vs. 9.8% of cases — a disparity arising because VDH routinely collected this information during case investigations for positive tests but not for negative ones. Among those with data, 3,924 (83.6%) identified as White and 500 (10.7%) as Black/African American, slightly lower than the 14.1% census estimate of the proportion of children under 5 who are non-Hispanic Black/African American in Southwest Virginia in 2022.¹⁰⁹ Given the large differential missingness, race/ethnicity was excluded from regression analyses.

Prior testing and positives

Overall, 17% of the cohort had at least one prior infection reported before vaccine eligibility, with a greater proportion among controls than cases (18% vs. 12%; Table 1). Forty-five percent had no prior tests reported, with fewer controls than cases in this category (41% vs. 54%). In summary, controls were more frequently tested and more likely to have had a prior positive than cases.

Vaccine coverage

Of the controls, 839 (16%) had more than one post-eligible negative test; differences between earliest and most-recent control scenarios are driven by these individuals. Overall vaccine

coverage was very low (<2%; Table 2). Of cases, 15 (0.9%) had received at least one dose before their positive test, compared to 92 (1.8%) and 99 (1.9%) of controls at earliest and most-recent tests, respectively. After applying the 7-day exclusion window, 8 (0.4%) cases had received 1 dose and 4 (0.2%) had received 2 doses; controls had 39 (0.8%) and 37 (0.7%) with 1 dose and 46 (0.9%) and 55 (1.1%) with ≥ 2 doses (earliest and most-recent, respectively). Of the 12 analytically vaccinated cases, 3 (0.2%) received Moderna and 9 (0.3%) received Pfizer-BioNTech. Of the controls, as of the earliest test, 29 (0.6%) received Moderna and 56 (1.1%) received Pfizer-BioNTech; as of the most-recent test, 32 (0.6%) received Moderna and 60 (1.1%) received Pfizer-BioNTech at least 7 days prior to their test.

Due to the small number of vaccinated individuals, vaccine types (Pfizer-BioNTech and Moderna) were combined, and vaccine status was defined by the number of doses received at least 7 days prior to the test (see Table 2). Mean days since vaccination for cases were 19 (1 dose) and 38 (2 doses); for controls, 32 and 40 days (earliest test) and 36 and 43 days (most-recent test) for 1 and ≥ 2 doses, respectively.

Vaccine Effectiveness and Logistic Regression Results

Unadjusted and adjusted VE results are presented in Table 3. One dose was associated with an unadjusted VE of 47% (95% CI: -7%, 77%; $p=0.100$) using the earliest test and 44% (-14%, 76%; $p=0.130$) using the most-recent test. Two or more doses yielded an unadjusted VE of 78% (95% CI: 45%, 93%; $p=0.004$) and 81% (54%, 94%; $p=0.001$), respectively. After adjustment for age, sex, prior positivity, and prior testing frequency, the estimates were modestly attenuated: 1 dose: 32% (-38%, 71%; $p=0.316$) and 29% (-46%, 70%; $p=0.382$); ≥ 2 doses: 70% (26%, 91%; $p=0.021$) and 76% (40%, 93%; $p=0.007$), for earliest and most-recent controls, respectively.

Categorical age was preferred based on AIC; results were robust to alternative age parameterizations (supplement Table S1).

Full multivariable results are in Table 4. Increasing age, prior negative tests, and prior positives were each significantly associated with lower odds of a reported positive test ($p < 0.05$); sex was not. Results were consistent across control selection scenarios and age parameterizations (supplement Table S1).

Stratified analyses (Table 5) showed that among children with no prior positive tests, 2 doses were associated with an OR of 0.26 (95% CI: 0.06, 0.72; $p = 0.025$), corresponding to a VE of 74% (95% CI: 28%, 94%). Among those with a prior positive, the OR associated with 2 doses was 0.55 (95% CI: 0.03, 3.02; $p = 0.569$), yielding a non-significant VE of 45% (95% CI: -302%, 97%). Younger age was associated with higher odds of infection in both strata. Prior negative tests were associated with lower odds only among those without a prior positive. Results were consistent across control scenarios and age parameterizations (supplement Tables S2, S3). The vaccine status effect was similar when health district was added to the multivariate models (see supplement: table S4).

Discussion

This study demonstrated that among children under 5 who became vaccine-eligible after the Omicron wave, vaccination — particularly ≥ 2 doses — significantly reduced reported infection risk. Prior infection was itself protective and attenuated the observed VE, consistent with the literature that natural infection confers partial immunity to reinfection¹¹⁰. Higher pre-eligibility testing frequency was also associated with lower odds of a subsequent reported infection, but

only among those without a prior positive — suggesting a systematic difference in risk between frequent and infrequent testers in this subgroup.

This study has several limitations. First, case and control classification relies solely on tests reported to VDH; rapid test results and unreported infections are not captured, and the test-negative design overrepresents symptomatic illness while underrepresenting mild or asymptomatic infections. Second, waning immunity was not modeled, though this is likely negligible given the brief analytic window and limited variant diversity during this period (Figure 1). Third, race and ethnicity could not be included in regression due to high missingness among controls. Fourth, low vaccine uptake precluded type-specific VE analyses. Fifth, VE against severity gradients or long-COVID could not be assessed. Sixth, post-eligibility test-seeking behavior — which may differ between vaccinated and unvaccinated — was not accounted for. Finally, because ORs overestimate relative risk when disease prevalence is high, VE estimates are likely conservative.¹¹¹

Conclusions:

This study found that vaccination was effective at reducing medically attended COVID-19 infections in this cohort. By focusing on the youngest children in an underrepresented rural region with disproportionately low uptake, this study contributes meaningfully to the pediatric COVID-19 VE literature and demonstrates the value of positive and negative surveillance data for real-world vaccine evaluation. While novel variants continue to emerge,¹¹² and children continue to have low vaccine uptake for COVID-19 vaccines⁷⁰ despite the recommendations by the CDC⁶⁶ and AAP,¹¹³ these results can help inform vaccine decisions and improve vaccine uptake for young children.

Acknowledgements

Thank you to the Virginia Department of Health and the Center for Biostatistics and Health Data Science at Virginia Tech.

References

1. The Centers for Disease Control and Prevention. Respiratory Virus Data Channel Weekly Snapshot. <https://www.cdc.gov/respiratory-viruses/data-research/dashboard/snapshot.html>. Published 2024. Accessed July 23 2024.
2. Xie Y, Choi T, Al-Aly Z. Postacute Sequelae of SARS-CoV-2 Infection in the Pre-Delta, Delta, and Omicron Eras. *N Engl J Med*. 2024.
3. Kratzer B, Gattinger P, Trapin D, Ettl P, Kormoczi U, Rottal A, et al. Differential decline of SARS-CoV-2-specific antibody levels, innate and adaptive immune cells, and shift of Th1/inflammatory to Th2 serum cytokine levels long after first COVID-19. *Allergy*. 2024.
4. Metz TD, Reeder HT, Clifton RG, Flaherman V, Aragon LV, Baucom LC, et al. Post-Acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) After Infection During Pregnancy. *Obstet Gynecol*. 2024.
5. Beladiya J, Kumar A, Vasava Y, Parmar K, Patel D, Patel S, et al. Safety and efficacy of COVID-19 vaccines: A systematic review and meta-analysis of controlled and randomized clinical trials. *Rev Med Virol*. 2024;34(1):e2507.
6. Piechotta V, Siemens W, Thielemann I, Toews M, Koch J, Vygen-Bonnet S, et al. Safety and effectiveness of vaccines against COVID-19 in children aged 5-11 years: a systematic review and meta-analysis. *Lancet Child Adolesc Health*. 2023;7(6):379-391.
7. Watanabe A, Kani R, Iwagami M, Takagi H, Yasuhara J, Kuno T. Assessment of Efficacy and Safety of mRNA COVID-19 Vaccines in Children Aged 5 to 11 Years: A Systematic Review and Meta-analysis. *JAMA Pediatr*. 2023;177(4):384-394.
8. Katoto PD, Tamuzi JL, Brand AS, Marangu DM, Byamungu LN, Wiysonge CS, et al. Effectiveness of COVID-19 Pfizer-BioNTech (BNT162b2) mRNA vaccination in adolescents aged 12-17 years: A systematic review and meta-analysis. *Hum Vaccin Immunother*. 2023;19(1):2214495.
9. Bobrovitz N, Ware H, Ma X, Li Z, Hosseini R, Cao C, et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. *Lancet Infect Dis*. 2023;23(5):556-567.
10. Xu S, Li J, Wang H, Wang F, Yin Z, Wang Z. Real-world effectiveness and factors associated with effectiveness of inactivated SARS-CoV-2 vaccines: a systematic review and meta-regression analysis. *BMC Med*. 2023;21(1):160.
11. Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. *Lancet*. 2022;399(10328):924-944.
12. Teerawattananon Y, Anothaisintawee T, Pheerapanyawaranun C, Botwright S, Akksilp K, Sirichumroonwit N, et al. A systematic review of methodological approaches for evaluating real-world effectiveness of COVID-19 vaccines: Advising resource-constrained settings. *PLoS One*. 2022;17(1):e0261930.
13. Wu N, Joyal-Desmarais K, Ribeiro PAB, Vieira AM, Stojanovic J, Sanuade C, et al. Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022. *Lancet Respir Med*. 2023;11(5):439-452.

14. Buonsenso D, Cusenza F, Passadore L, Bonanno F, De Guido C, Esposito S. Duration of immunity to SARS-CoV-2 in children after natural infection or vaccination in the omicron and pre-omicron era: A systematic review of clinical and immunological studies. *Front Immunol*. 2022;13:1024924.
15. Twohig KA, Nyberg T, Zaidi A, Thelwall S, Sinnathamby MA, Aliabadi S, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. *Lancet Infect Dis*. 2022;22(1):35-42.
16. Ma KC, Dorabawila V, Leon TM, Henry H, Johnson AG, Rosenberg E, et al. Trends in Laboratory-Confirmed SARS-CoV-2 Reinfections and Associated Hospitalizations and Deaths Among Adults Aged \geq 18 Years - 18 U.S. Jurisdictions, September 2021-December 2022. *MMWR Morb Mortal Wkly Rep*. 2023;72(25):683-689.
17. Nguyen NN, Nguyen YN, Hoang VT, Million M, Gautret P. SARS-CoV-2 Reinfection and Severity of the Disease: A Systematic Review and Meta-Analysis. *Viruses*. 2023;15(4).
18. Iuliano AD, Brunkard JM, Boehmer TK, Peterson E, Adjei S, Binder AM, et al. Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods - United States, December 2020-January 2022. *MMWR Morb Mortal Wkly Rep*. 2022;71(4):146-152.
19. Wanga V, Gerdes ME, Shi DS, Choudhary R, Dulski TM, Hsu S, et al. Characteristics and Clinical Outcomes of Children and Adolescents Aged $<$ 18 Years Hospitalized with COVID-19 - Six Hospitals, United States, July-August 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70(5152):1766-1772.
20. Martin B, DeWitt PE, Russell S, Anand A, Bradwell KR, Bremer C, et al. Characteristics, Outcomes, and Severity Risk Factors Associated With SARS-CoV-2 Infection Among Children in the US National COVID Cohort Collaborative. *JAMA Netw Open*. 2022;5(2):e2143151.
21. Head JR, Collender PA, Leon TM, White LA, Sud SR, Camponuri SK, et al. COVID-19 Vaccination and Incidence of Pediatric SARS-CoV-2 Infection and Hospitalization. *JAMA Netw Open*. 2024;7(4):e247822.
22. Marks KJ, Whitaker M, Agathis NT, Anglin O, Milucky J, Patel K, et al. Hospitalization of Infants and Children Aged 0-4 Years with Laboratory-Confirmed COVID-19 - COVID-NET, 14 States, March 2020-February 2022. *MMWR Morb Mortal Wkly Rep*. 2022;71(11):429-436.
23. Hageman JR. Long COVID-19 or Post-Acute Sequelae of SARS-CoV-2 Infection in Children, Adolescents, and Young Adults. *Pediatr Ann*. 2021;50(6):e232-e233.
24. Rao S, Lee GM, Razzaghi H, Lorman V, Mejias A, Pajor NM, et al. Clinical Features and Burden of Postacute Sequelae of SARS-CoV-2 Infection in Children and Adolescents. *JAMA Pediatr*. 2022;176(10):1000-1009.
25. Malone LA, Morrow A, Chen Y, Curtis D, de Ferranti SD, Desai M, et al. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of postacute sequelae of SARS-CoV-2 infection (PASC) in children and adolescents. *PM R*. 2022;14(10):1241-1269.
26. Buonsenso D. Further evidence from a large US electronic health record-based study that some children and adolescents can develop postacute sequelae of SARS-CoV-2 infection. *Evid Based Nurs*. 2023;26(3):97.
27. Mejias A, Schuchard J, Rao S, Bennett TD, Jhaveri R, Thacker D, et al. Leveraging Serologic Testing to Identify Children at Risk For Post-Acute Sequelae of SARS-CoV-2 Infection: An Electronic Health Record-Based Cohort Study from the RECOVER Program. *J Pediatr*. 2023;257:113358.
28. Rahmati M, Yon DK, Lee SW, Udeh R, Mc EM, Kim MS, et al. New-onset type 1 diabetes in children and adolescents as postacute sequelae of SARS-CoV-2 infection: A systematic review and meta-analysis of cohort studies. *J Med Virol*. 2023;95(6):e28833.
29. Rao S, Gross RS, Mohandas S, Stein CR, Case A, Dreyer B, et al. Postacute Sequelae of SARS-CoV-2 in Children. *Pediatrics*. 2024;153(3).

30. Parzen-Johnson S, Katz BZ. Navigating the Spectrum of Two Pediatric COVID-19 Complications: Multi-System Inflammatory Syndrome in Children and Post-Acute Sequelae of SARS-CoV-2 Infection. *J Clin Med*. 2024;13(4).
31. DiMura PM, Wagner VL, Robertson TW, Wu M, Conroy MB, Josberger R. Identifying Post-Acute Sequelae of SARS-CoV-2 Among Children in New York State Medicaid Managed Care. *J Community Health*. 2024.
32. Maeda M, Murata F, Fukuda H. Effect of COVID-19 Vaccination on Household Transmission of SARS-CoV-2 in the Omicron Era: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study. *Int J Infect Dis*. 2023.
33. Zhu Y, Xia Y, Pickering J, Bowen AC, Short KR. The role of children in transmission of SARS-CoV-2 variants of concern within households: an updated systematic review and meta-analysis, as at 30 June 2022. *Euro Surveill*. 2023;28(18).
34. Tseng YJ, Olson KL, Bloch D, Mandl KD. Smart Thermometer-Based Participatory Surveillance to Discern the Role of Children in Household Viral Transmission During the COVID-19 Pandemic. *JAMA Netw Open*. 2023;6(6):e2316190.
35. Baker JM, Nakayama JY, O'Hegarty M, McGowan A, Teran RA, Bart SM, et al. SARS-CoV-2 B.1.1.529 (Omicron) Variant Transmission Within Households - Four U.S. Jurisdictions, November 2021-February 2022. *MMWR Morb Mortal Wkly Rep*. 2022;71(9):341-346.
36. Oberg C, Hodges HR, Gander S, Nathawad R, Cutts D. The impact of COVID-19 on children's lives in the United States: Amplified inequities and a just path to recovery. *Curr Probl Pediatr Adolesc Health Care*. 2022;52(7):101181.
37. Food and Drug Administration. FDA Takes Action on Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants. 2023.
38. Food and Drug Administration. FDA Briefing Document: Future Vaccination Regimens Addressing COVID-19. 2023.
39. Food and Drug Administration. Updated COVID-19 Vaccines for Use in the United States Beginning in Fall 2023. 2023.
40. Nextstrain. Genomic epidemiology of SARS-CoV-2 with subsampling focused globally over the past 6 months. <https://nextstrain.org/ncov/gisaid/global/6m?d=tree&p=full>. Published 2023.
41. Biobot Analytics. Covid-19 Wastewater Monitoring in the U.S. <https://biobot.io/data/>. Published 2023.
42. Clarke KEN, Jones JM, Deng Y, Nycz E, Lee A, Iachan R, et al. Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies - United States, September 2021-February 2022. *MMWR Morb Mortal Wkly Rep*. 2022;71(17):606-608.
43. Department of Health and Human Services Assistant Secretary for Public Affairs. COVID-19 Vaccine Milestones. 2023(June 29, 2023).
44. Food and Drug Administration. FDA Roundup: April 28, 2023. 2023.
45. The Centers for Disease Control and Prevention. CDC simplifies COVID-19 vaccine recommendations, allows older adults and immunocompromised adults to get second dose of the updated vaccine. 2023.
46. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Changes to Simplify Use of Bivalent mRNA COVID-19 Vaccines. 2023.
47. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Bivalent Pfizer-BioNTech COVID-19 Vaccine as Booster Dose for Certain Children 6 Months through 4 Years of Age. 2023.
48. The Centers for Disease Control and Prevention. CDC Expands Updated COVID-19 Vaccines to Include Children Ages 6 Months through 5 Years. 2022.

49. The Centers for Disease Control and Prevention. CDC Expands Updated COVID-19 Vaccines to Include Children Ages 5 Through 11. 2022.
50. The Centers for Disease Control and Prevention. CDC Recommends the First Updated COVID-19 Booster. 2022.
51. The Centers for Disease Control and Prevention. CDC Recommends Moderna COVID-19 Vaccine for Children and Adolescents. 2022.
52. The Centers for Disease Control and Prevention. CDC Recommends COVID-19 Vaccines for Young Children. 2022.
53. The Centers for Disease Control and Prevention. CDC Strengthens Recommendations and Expands Eligibility for COVID-19 Booster Shots. 2022.
54. The Centers for Disease Control and Prevention. CDC Recommends Additional Boosters for Certain Individuals. 2022.
55. The Centers for Disease Control and Prevention. CDC Expands Booster Shot Eligibility and Strengthens Recommendations for 12-17 Year Olds. 2022.
56. The Centers for Disease Control and Prevention. CDC Expands COVID-19 Booster Recommendations to 16-and-17-year-olds. 2021.
57. The Centers for Disease Control and Prevention. CDC Expands COVID-19 Booster Recommendations. 2021.
58. Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020. *MMWR Morb Mortal Wkly Rep.* 2021;69(5152):1653-1656.
59. Oliver SE, Gargano JW, Scobie H, Wallace M, Hadler SC, Leung J, et al. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Janssen COVID-19 Vaccine - United States, February 2021. *MMWR Morb Mortal Wkly Rep.* 2021;70(9):329-332.
60. Wallace M, Woodworth KR, Gargano JW, Scobie HM, Blain AE, Moulia D, et al. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12-15 Years - United States, May 2021. *MMWR Morb Mortal Wkly Rep.* 2021;70(20):749-752.
61. Woodworth KR, Moulia D, Collins JP, Hadler SC, Jones JM, Reddy SC, et al. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5-11 Years - United States, November 2021. *MMWR Morb Mortal Wkly Rep.* 2021;70(45):1579-1583.
62. Twentyman E, Wallace M, Roper LE, Anderson TC, Rubis AB, Fleming-Dutra KE, et al. Interim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19 Vaccine in Persons Aged ≥ 18 years - United States, July 2022. *MMWR Morb Mortal Wkly Rep.* 2022;71(31):988-992.
63. Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(50):1922-1924.
64. Food and Drug Administration. Updated COVID-19 Vaccines for Use in the United States Beginning in Fall 2024. 2024.
65. Fleming-Dutra KE, Wallace M, Moulia DL, Twentyman E, Roper LE, Hall E, et al. Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months-5 Years - United States, June 2022. *MMWR Morb Mortal Wkly Rep.* 2022;71(26):859-868.
66. Centers for Disease Control and Prevention. CDC Recommends Updated 2024-2025 COVID-19 and Flu Vaccines for Fall/Winter Virus Season. In: Services USDoHH, editor. 2024.

67. Murthy BP, Fast HE, Zell E, Murthy N, Meng L, Shaw L, et al. COVID-19 Vaccination Coverage and Demographic Characteristics of Infants and Children Aged 6 Months-4 Years - United States, June 20-December 31, 2022. *MMWR Morb Mortal Wkly Rep.* 2023;72(7):183-189.
68. Centers for Disease Control and Prevention. For immunization managers: COVID-19 vaccination coverage and vaccine confidence among children. Atlanta, GA: US Department of Health and Human Services; 2022. <https://www.cdc.gov/vaccines/imz-managers/coverage/covidvaxview/interactive/children.html>. Published 2024.
69. Khazanchi R, Rader B, Cantor J, McManus KA, Bravata DM, Weintraub R, et al. Spatial Accessibility and Uptake of Pediatric COVID-19 Vaccinations by Social Vulnerability. *Pediatrics.* 2024.
70. Centers for Disease Control and Prevention. COVID-19 Vaccination Coverage and Intent for Vaccination, Children 6 months through 17 years, United States. <https://www.cdc.gov/covidvaxview/weekly-dashboard/child-coverage-vaccination.html>. Published 2025.
71. Santibanez TA, Black CL, Zhou T, Srivastav A, Singleton JA. Parental hesitancy about COVID-19, influenza, HPV, and other childhood vaccines. *Vaccine.* 2024.
72. Amir O, Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, et al. Initial protection against SARS-CoV-2 omicron lineage infection in children and adolescents by BNT162b2 in Israel: an observational study. *Lancet Infect Dis.* 2023;23(1):67-73.
73. Castelli JM, Rearte A, Olszevicki S, Voto C, Del Valle Juarez M, Pesce M, et al. Effectiveness of mRNA-1273, BNT162b2, and BBIBP-CorV vaccines against infection and mortality in children in Argentina, during predominance of delta and omicron covid-19 variants: test negative, case-control study. *BMJ.* 2022;379:e073070.
74. Chemaitelly H, AlMukdad S, Ayoub HH, Altarawneh HN, Coyle P, Tang P, et al. Covid-19 Vaccine Protection among Children and Adolescents in Qatar. *N Engl J Med.* 2022;387(20):1865-1876.
75. Ciesla AA, Wiegand RE, Smith ZR, Britton A, Fleming-Dutra KE, Miller J, et al. Effectiveness of Booster Doses of Monovalent mRNA COVID-19 Vaccine Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children, Adolescents, and Adults During Omicron Subvariant BA.2/BA.2.12.1 and BA.4/BA.5 Predominant Periods. *Open Forum Infect Dis.* 2023;10(5):ofad187.
76. Cohen-Stavi CJ, Magen O, Barda N, Yaron S, Peretz A, Netzer D, et al. BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age. *N Engl J Med.* 2022;387(3):227-236.
77. Creech CB, Anderson E, Berthaud V, Yildirim I, Atz AM, Melendez Baez I, et al. Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age. *N Engl J Med.* 2022;386(21):2011-2023.
78. Feldstein LR, Britton A, Grant L, Wiegand R, Ruffin J, Babu TM, et al. Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years. *JAMA.* 2024;331(5):408-416.
79. Fleming-Dutra KE, Britton A, Shang N, Derado G, Link-Gelles R, Accorsi EK, et al. Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance. *JAMA.* 2022;327(22):2210-2219.
80. Fowlkes AL, Yoon SK, Lutrick K, Gwynn L, Burns J, Grant L, et al. Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022. *MMWR Morb Mortal Wkly Rep.* 2022;71(11):422-428.
81. Jayaraj VJ, Husin M, Suah JL, Tok PSK, Omar A, Rampal S, et al. Effectiveness of COVID-19 vaccines among children 6-11 years against hospitalization during Omicron predominance in Malaysia. *Sci Rep.* 2024;14(1):5690.
82. Khan FL, Nguyen JL, Singh TG, Puzniak LA, Wiemken TL, Schrecker JP, et al. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age. *JAMA Netw Open.* 2022;5(12):e2246915.

83. Klein NP, Stockwell MS, Demarco M, Gaglani M, Kharbanda AB, Irving SA, et al. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022. *MMWR Morb Mortal Wkly Rep.* 2022;71(9):352-358.
84. Lin DY, Gu Y, Wheeler B, Young H, Holloway S, Sunny SK, et al. Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina. *N Engl J Med.* 2022;386(10):933-941.
85. Lin DY, Gu Y, Xu Y, Zeng D, Wheeler B, Young H, et al. Effects of Vaccination and Previous Infection on Omicron Infections in Children. *N Engl J Med.* 2022;387(12):1141-1143.
86. Olson SM, Newhams MM, Halasa NB, Price AM, Boom JA, Sahni LC, et al. Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents. *N Engl J Med.* 2022;386(8):713-723.
87. Price AM, Olson SM, Newhams MM, Halasa NB, Boom JA, Sahni LC, et al. BNT162b2 Protection against the Omicron Variant in Children and Adolescents. *N Engl J Med.* 2022;386(20):1899-1909.
88. Razzaghi H, Forrest CB, Hirabayashi K, Wu Q, Allen A, Rao S, et al. Vaccine Effectiveness Against Long COVID in Children: A Report from the RECOVER EHR Cohort. *medRxiv.* 2023.
89. Razzaghi H, Forrest CB, Hirabayashi K, Wu Q, Allen AJ, Rao S, et al. Vaccine Effectiveness Against Long COVID in Children. *Pediatrics.* 2024;153(4).
90. Sacco C, Del Manso M, Mateo-Urdiales A, Rota MC, Petrone D, Riccardo F, et al. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022. *Lancet.* 2022;400(10346):97-103.
91. Tan SHX, Cook AR, Heng D, Ong B, Lye DC, Tan KB. Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age. *N Engl J Med.* 2022;387(6):525-532.
92. Tang P, Hasan MR, Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. *Nat Med.* 2021;27(12):2136-2143.
93. Wu Q, Tong J, Zhang B, Zhang D, Chen J, Lei Y, et al. Real-World Effectiveness of BNT162b2 Against Infection and Severe Diseases in Children and Adolescents. *Ann Intern Med.* 2024;177(2):165-176.
94. Zambrano LD, Newhams MM, Olson SM, Halasa NB, Price AM, Boom JA, et al. Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12-18 Years - United States, July-December 2021. *MMWR Morb Mortal Wkly Rep.* 2022;71(2):52-58.
95. Anderson EJ, Creech CB, Berthaud V, Piramzadian A, Johnson KA, Zervos M, et al. Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age. *N Engl J Med.* 2022;387(18):1673-1687.
96. Fleming-Dutra KE, Ciesla AA, Roper LE, Smith ZR, Miller JD, Accorsi EK, et al. Preliminary Estimates of Effectiveness of Monovalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection Among Children Aged 3-5 Years - Increasing Community Access to Testing Program, United States, July 2022-February 2023. *MMWR Morb Mortal Wkly Rep.* 2023;72(7):177-182.
97. Lin DY, Xu Y, Gu Y, Zeng D, Wheeler B, Young H, et al. Effects of COVID-19 vaccination and previous SARS-CoV-2 infection on omicron infection and severe outcomes in children under 12 years of age in the USA: an observational cohort study. *Lancet Infect Dis.* 2023.
98. Link-Gelles R, Ciesla AA, Rowley EAK, Klein NP, Naleway AL, Payne AB, et al. Effectiveness of Monovalent and Bivalent mRNA Vaccines in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters Among Children Aged 6 Months-5 Years - VISION Network, United States, July 2022-June 2023. *MMWR Morb Mortal Wkly Rep.* 2023;72(33):886-892.
99. Munoz FM, Sher LD, Sabharwal C, Gurtman A, Xu X, Kitchin N, et al. Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age. *N Engl J Med.* 2023;388(7):621-634.
100. Tannis A, Englund JA, Perez A, Harker EJ, Staat MA, Schlaudecker EP, et al. SARS-CoV-2 Epidemiology and COVID-19 mRNA Vaccine Effectiveness Among Infants and Children Aged 6

- Months-4 Years - New Vaccine Surveillance Network, United States, July 2022-September 2023. *MMWR Morb Mortal Wkly Rep.* 2023;72(48):1300-1306.
101. Washington State Department of Health. Guidelines for Using Racial and Ethnic Groupings in Data Analyses. 2010.
 102. Virginia Department of Health. Localities by Health District. <https://www.vdh.virginia.gov/local-health-districts/>. Published 2020.
 103. Team P. RStudio: Integrated Development Environment for R. In: Posit Software P, editor. Boston, MA2025.
 104. Team RC. R: A Language and Environment for Statistical Computing. In: Computing RFFS, editor. Vienna, Austria2025.
 105. OpenAI. ChatGPT. <https://chat.openai.com/>. Published 2026.
 106. Wickham H, Averick M, Bryan J, Chang W, McGowan L, François R, et al. Welcome to the tidyverse. *Journal of Open Source Software.* 2019;4(43):1686.
 107. Sjoberg D, Whiting K, Curry M, Lavery J, Larmarange J. Reproducible Summary Tables with the gtsummary Package. *The R Journal.* 2021(13):570-580.
 108. Spina A, Kamvar Z, Schumacher D. epikit: Miscellaneous Helper Tools for Epidemiologists. 2024.
 109. Virginia Department of Health. VDH Virginia Single-Race Population Estimates. <https://data.virginia.gov/dataset/vdh-virginia-single-race-population-estimates>. Published 2025.
 110. Chemaitelly H, Ayoub HH, Coyle P, Tang P, Hasan MR, Yassine HM, et al. Differential protection against SARS-CoV-2 reinfection pre- and post-Omicron. *Nature.* 2025;639(8056):1024-1031.
 111. Celentano DD, Szklo M, Gordis L. *Gordis epidemiology*. 6th edition. ed. Philadelphia, PA: Elsevier; 2019.
 112. Nextstrain. Genomic epidemiology of SARS-CoV-2 with subsampling focused globally over the past 6 months. <https://nextstrain.org/ncov/gisaid/global/6m>. Published 2025.
 113. Committee on Infectious D. Recommendations for COVID-19 Vaccines in Infants, Children, and Adolescents: Policy Statement. *Pediatrics.* 2025;156(5).

Legends:

Figure 1.

CDC COVID-19 vaccine recommendation timeline, superimposed over US reported daily cases (incidence) and SARS-CoV-2 wastewater concentrations (prevalence) from Biobot Analytics, Inc. (used with permission). Age-group and other eligibility criteria in brackets; vaccine type: primary series (bold border); 2020/2021-wild-type (blue), 2021/2022-wild-type-booster (purple), 2022/2023-wild-type/omicron bivalent-booster (red), second-bivalent-booster (pink), and 2023/2024-monovalent XBB.1.5 (green).

Figure 2. Inclusion and exclusion criteria flow-chart for selection into test-negative case-control cohort.

Alt Text:

Figure 1 Alt Text: Timeline of COVID-19 Pfizer-BioNTech (Pfizer), Moderna, and Novavax CDC recommendations by age-group and temporal trends in SARS-CoV-2 incidence and prevalence from clinical case reports and waste-water surveillance. Note that the CDC approved the initial primary series for children 6 months to 5 years in June 2022, after the Omicron wave

during the prior winter, lagging over a year behind adult and older adolescent approval in April and May, 2021, and 7 months after the 5-11 year old age-group approval in November, 2021.

Figure 2 Alt Text: Flow chart for selection into analytic case-control study cohort. From 303,191 records, excluding duplicates and those that do not meet inclusion criteria. Ultimately identifying 1,987 cases and 5,178 controls included in the analysis cohort.


Table 1 Alt Text: Descriptive statistics of study cohort characteristics, including age, sex, race/ethnicity, prior positive, negative, and any tests reported. Differences were observed with controls having greater proportion of individuals with prior tests (positive and negative), missing more race/ethnicity data, and having a smaller proportion of children under 1 years-old than cases.

Table 2 Alt Text: Vaccine status frequencies at the time of the analytic test for cases and controls, by type (Moderna vs. Pfizer BioNTech), number of doses, and mean number of days since the most recent vaccine.

Table 3 Alt Text: Vaccine effectiveness estimates by number of doses calculated from odds ratios from unadjusted and adjusted logistic regression. Adjusted analyses found the VE was attenuated relative to unadjusted results but remained statistically significantly effective when comparing those with 2 doses to unvaccinated.

Table 4 Alt Text: Multivariable (adjusted) logistic regression model results, presenting odds ratios for a positive reported test for all variables included in the model: vaccine status, sex, age, prior positive test, and prior negative tests.

Table 5 Alt Text: Multivariable (adjusted) logistic regression model results stratified by prior positive test, presenting odds ratios for a positive reported test for all variables included in the model: vaccine status, sex, age, and prior negative tests. Note that the vaccine effectiveness was much greater among those with no prior positive test compared to those with a prior positive test.






Table 1. Characteristics of study cohort by overall and by case and control* status.

Characteristic		Overall (N=7,165)	Cases (N=1,987)	Controls (N=5,178)
Age at test (years)	Mean (SD)	2.58 (1.36)	2.32 (1.38)	2.68 (1.33)
	Median [Min, Max]	2.52 [0.5, 5]	2.04 [0.5, 5]	2.69 [0.5, 5]
Age (years) Groups	6m to <1yr	1,127 (15.7%)	467 (23.5%)	660 (12.8%)
	1 yrs	1,757 (24.5%)	505 (25.4%)	1,252 (24.2%)
	2 yrs	1,357 (18.9%)	343 (17.3%)	1,014 (19.6%)
	3 yrs	1,466 (20.5%)	335 (16.9%)	1,131 (21.8%)
	4 yrs	1,458 (20.3%)	337 (17.0%)	1,121 (21.6%)
Sex	Female	3,390 (47.3%)	932 (46.9%)	2,458 (47.5%)
	Male	3,734 (52.1%)	1,053 (53.0%)	2,681 (51.8%)
	Unknown/missing	41 (0.6%)	2 (0.1%)	39 (0.8%)
Race/Ethnicity**	White	3,924 (54.7%; 83.6%)	1,414 (71.2%; 78.9%)	2,510 (48.4%; 86.5%)
	Black	500 (7.0%; 10.7%)	237 (11.9%; 13.2%)	263 (5.1%; 9.1%)
	Asian	43 (0.6%; 0.9%)	20 (1.0%; 1.1%)	23 (0.4%; 0.8%)
	Hispanic	96 (1.3%; 2.0%)	96 (4.8%; 5.4%)	0 (0%; 0%)
	Other	128 (1.8%; 2.7%)	26 (1.3%; 1.5%)	102 (2.0%; 3.5%)
	Unknown/missing	2,474 (34.5%; na)	194 (9.8%; na)	2,280 (44.0%; na)
Prior Positive Test Reported	none	5,959 (83.2%)	1,742 (87.7%)	4,217 (81.4%)
	1 or more	1,206 (16.8%)	245 (12.3%)	961 (18.6%)
Prior Tests Reported (any)	None	3,227 (45.0%)	1,082 (54.5%)	2,145 (41.4%)
	1 to 3	3,347 (46.7%)	779 (39.2%)	2,568 (49.6%)
	4 or more	591 (8.2%)	126 (6.3%)	465 (9.0%)
Prior Negative Test Reported	None	3,654 (51.0%)	1,174 (59.1%)	2,480 (47.9%)
	1 to 3	3,092 (43.2%)	721 (36.3%)	2,371 (45.8%)
	4 or more	419 (5.8%)	92 (4.6%)	327 (6.3%)

*As of the date of their earliest post-vaccine eligible test (for controls)
 **N (% of total including unknown; % of total excluding unknown)

Table 2. Vaccine status* at the time of the analytic test for cases and controls.

Type and Number of Vaccine Doses prior to test		Cases (N=1,987)	Controls (N=5,178) Earliest test	Controls (N=5,178) Most-recent test
Unvaccinated	0 doses	1,972 (99.2%)	5,086 (98.2%)	5,079 (98.1%)
Moderna	1 dose within 7 days	0 (0%)	2 (0.0%)	2 (0.0%)
	1 dose	2 (0.1%)	15 (0.3%)	14 (0.3%)
	2 doses	1 (0.1%)	14 (0.3%)	18 (0.3%)
Pfizer-BioNTech	1 dose within 7 days	3 (0.2%)	5 (0.1%)	5 (0.1%)
	1 dose	6 (0.3%)	24 (0.5%)	23 (0.4%)
	2 doses	3 (0.2%)	28 (0.5%)	33 (0.6%)
	3 doses	0 (0%)	4 (0.1%)	4 (0.1%)
Combined (analysis)*	Unvaccinated	1,975 (99.4%)	5,093 (98.4%)	5,086 (98.2%)
	1 dose	8 (0.4%)	39 (0.8%)	37 (0.7%)
	Mean (min-max) days since vaccine	19 days (8-27)	32 (10-99)	36 (10-99)
	2 or more doses	4 (0.2%)	46 (0.9%)	55 (1.1%)
	Mean (min-max) days since vaccine	38 (10-75)	40 (8-96)	43 (8-96)

*Those vaccinated with their first dose with 7 days of test are included in unvaccinated, those vaccinated with a second dose within 7 days are included in 1 dose.

Table 3. Vaccine effectiveness* by number of doses calculated from odds ratios from unadjusted and adjusted logistic regression.

Unadjusted	
Control is earliest eligible test	Control is most-recent eligible test

	OR (95% CI)	VE (95% CI)	P-value	OR (95% CI)	VE (95% CI)	P-value
1 dose	0.53 (0.23, 1.07)	47% (-7%, 77%)	0.102	0.56 (0.24, 1.14)	44% (-14%, 76%)	0.134
2 doses	0.22 (0.07, 0.55)	78% (45%, 93%)	0.004	0.19 (0.06, 0.46)	81% (54%, 94%)	0.001
Adjusted for age (categorical), sex, prior positivity, prior testing frequency						
	Control is earliest eligible test			Control is most-recent eligible test		
	OR (95% CI)	VE (95% CI)	P-value	OR (95% CI)	VE (95% CI)	P-value
1 dose	0.68 (0.29, 1.38)	32% (-38%, 71%)	0.316	0.71 (0.30, 1.46)	29% (-46%, 70%)	0.382
2 doses	0.30 (0.09, 0.74)	70% (26%, 91%)	0.021	0.24 (0.07, 0.60)	76% (40%, 93%)	0.007
Abbreviations: OR: odds ratio, VE: vaccine effectiveness, CI: confidence interval, Ref: reference group						
P-value<0.05 in bold						

Table 4. Multivariable (adjusted) logistic regression model results.

Characteristic		Control is earliest eligible test		Control is most-recent eligible test	
		OR (95% CI)	p-value	OR (95% CI)	p-value
Vaccine Status	Unvaccinated	Ref	Ref	Ref	Ref
	1dose	0.68 (0.29, 1.38)	0.316	0.71 (0.30, 1.46)	0.382
	2 doses	0.30 (0.09, 0.74)	0.021	0.24 (0.07, 0.60)	0.007
Sex	Female	Ref	Ref	Ref	Ref
	Male	1.04 (0.94, 1.16)	0.416	1.04 (0.94, 1.16)	0.416
Age (years) Categorical	<1	Ref	Ref	Ref	Ref
	1-<2	0.63 (0.54, 0.74)	<0.001	0.60 (0.51, 0.70)	<0.001
	2-<3	0.54 (0.46, 0.65)	<0.001	0.52 (0.43, 0.62)	<0.001
	3-<4	0.47 (0.40, 0.56)	<0.001	0.46 (0.38, 0.54)	<0.001
	4+	0.49 (0.41, 0.58)	<0.001	0.46 (0.38, 0.54)	<0.001
Prior Positive	none	Ref	Ref	Ref	Ref
	1 or more	0.67 (0.57, 0.78)	<0.001	0.67 (0.57, 0.78)	<0.001
Prior Negative Tests	None	Ref	Ref	Ref	Ref
	1 to 3	0.73 (0.65, 0.81)	<0.001	0.73 (0.66, 0.82)	<0.001
	4 or more	0.73 (0.57, 0.93)	0.013	0.74 (0.58, 0.94)	0.017
Abbreviations: OR: odds ratio, CI: confidence interval, Ref: reference group					
P-value<0.05 in bold					

Table 5. Multivariable logistic regression model results, stratified by prior positivity.

Characteristic		No Prior Positive Test (N = 5,959)		Any Prior Positive Test (N = 1,206)	
		OR (95% CI)	p-value	OR (95% CI)	p-value
Earliest Test for Controls					
Vaccine Status	unvaccinated	Ref	Ref	Ref	Ref
	1dose	0.76 (0.30, 1.65)	0.513	0.41 (0.02, 2.17)	0.397
	2doses	0.26 (0.06, 0.72)	0.025	0.54 (0.03, 3.01)	0.568
Sex	Female	Ref	Ref	Ref	Ref
	Male	1.05 (0.94, 1.18)	0.402	1.00 (0.76, 1.34)	0.979
Age (years) Categorical	<1	Ref	Ref	Ref	Ref
	1-<3	0.59 (0.50, 0.69)	<0.001	0.65 (0.42, 1.02)	0.057
	3+	0.49 (0.42, 0.57)	<0.001	0.44 (0.27, 0.71)	<0.001
Prior Negative Tests	none	Ref	Ref	Ref	Ref
	1 to 3	0.70 (0.62, 0.79)	<0.001	0.98 (0.72, 1.33)	0.877
	4 or more	0.64 (0.48, 0.85)	0.003	1.14 (0.68, 1.86)	0.618
Most-recent Test for Controls					
Vaccine Status	unvaccinated	Ref	Ref	Ref	Ref
	1dose	0.81 (0.32, 1.77)	0.620	0.43 (0.02, 2.26)	0.418
	2doses	0.21 (0.05, 0.57)	0.009	0.48 (0.03, 2.57)	0.484
Sex	Female	Ref	Ref	Ref	Ref
	Male	1.05 (0.94, 1.18)	0.397	1.01 (0.76, 1.34)	0.972

Age (years)	<1	Ref	Ref	Ref	Ref
Categorical	1-<3	0.56 (0.48, 0.65)	<0.001	0.60 (0.39, 0.94)	0.023
	3+	0.47 (0.40, 0.55)	<0.001	0.39 (0.25, 0.64)	<0.001
Prior	none	Ref	Ref	Ref	Ref
Negative	1 to 3	0.70 (0.62, 0.79)	<0.001	0.99 (0.73, 1.36)	0.962
Tests	4 or more	0.65 (0.49, 0.86)	0.003	1.17 (0.70, 1.92)	0.540
Abbreviations: OR: odds ratio, CI: confidence interval, Ref: reference group					
P-value<0.05 in bold					